Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 3Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Smoking Cessation 1Sexual Dysfunctions, Psychological 1Ovarian Neoplasms 1Obesity 1Neoplasms, Second Primary 1Metabolic Syndrome 1Inflammation 1Hematopoietic and Lymphatic System Neoplasm 1Healthy Adult Participants 1Dyslipidemias 1Carcinoma, Non-Small-Cell Lung 1Behavior, Addictive 1

Interventions

pembrolizumab 4aldesleukin 3Cisplatin 3lenvatinib 2Surveys and Questionnaires 2Specimen Handling 2Paclitaxel 2Nivolumab 2Methods 2Magnetic Resonance Spectroscopy 2Adoptive Transfer 2zimberelimab 1trastuzumab deruxtecan 1tivozanib 1liposomal doxorubicin 1fludarabine phosphate 1fludarabine 1entinostat 1dostarlimab 1cemiplimab 1bintrafusp alfa protein, human 1belzutifan 1atezolizumab 1Therapeutic Touch 1Taxes 1Standard of Care 1Sonazoid 1Respiratory Function Tests 1Radiotherapy 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vulvar Neoplasms × Bupropion × 1 year × Clear all
NCT03180294 2026-05-19

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NRG Oncology

Phase 2 Completed
230 enrolled 24 charts
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡